Approaches to HIV Eradication
Toulon, France, August 30, 2011 - What can be done about HIV eradication? The advancements in scientific technology and medical treatments have made significant progress in managing HIV and making it a chronic condition in most patients; however, the next logical step toward a cure has been elusive. Researchers have been working hard for the past few years on closing the gap between manageable disease and functional cure, and several different approaches have been explored or are currently being discussed. While antiretroviral therapy (ART) has been effective against HIV virus out in the open bloodstream, there are pockets of HIV that lie dormant in cells until antiretroviral therapy ceases, which allow them to become active again. These pockets are called HIV reservoirs. The approaches to HIV eradication focus mainly on how to deal with these reservoirs.
Let's talk about some of the discussed approaches; seven of them to be exact. On one approach, ART is started before HIV has a chance to establish reservoirs. This normally takes place when a person is just infected with HIV (acute HIV infection), very early in the process. The hope is to stop viruses before reservoirs can be established. In another approach, ART is intensified greatly in order to stop completely HIV replication. An alternate strategy is to activate dormant T-cells so the remaining HIV reservoirs can be flushed out and eliminated.
There are also strategies that deal with preventing the virus from infecting additional cells directly. If the HIV reservoirs can't be eliminated, one approach involves keeping the reservoirs dormant forever, keeping the HIV from ever replicating again. This means finding ways to disable the virus's ability to replicate. Alternatively, a sixth strategy protects the uninfected cells from ever being infected. The seventh discussed approach attempts to strengthen the body's natural immune system when exposed to HIV, very much like how a vaccine works.
The various approaches to HIV eradication all address a problem, and that problem is the HIV reservoir. HIV reservoirs have been called the last hiding place for HIV within the body. The final step toward finding a functional cure for HIV lies in dealing with HIV reservoirs. The dormant viruses hiding in these places make it very easy for a person's viral load to increase dramatically if ART is stopped even for a short time. Therefore, in conjunction with ART, one of the known possible approaches for HIV eradication—or possibly approaches that haven't been thought of yet—will become increasingly important to develop and implement.
1208 Av. Cl Picot
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Approaches to HIV Eradication here
News-ID: 189919 • Views: 1818
More Releases from AVPS
New Trends Towards HIV Cure Research
Fifteen years after the advent of combined antiretroviral therapy (ART) life expectancy of HIV-infected patients, as well as their quality of life, have considerably improved. However, ART remains a life long battle as these therapies are unable to eradicate the virus. Although we can still improve tolerance and acceptability of ART, the next decisive step would be to find a cure. Specific budget lines have been created in 2010 and
Clues to HIV Persistence on ART
Recent research has found that while antiretroviral therapy (ART) is effective at significantly reducing the number of plasma-to-T-cell transmissions of HIV, it's not as effective against T-cell-to-T-cell. The remaining virus hides in infected T-cells, which allows it to easily be passed on to non-infected ones; this, in fact, is one of the reasons why HIV persists through ART. Toulon, France, August 23, 2011 - HIV has a built-in backup plan when
HIV Reservoirs Cure Research – More Investments Are Needed
Toulon, France, January 12, 2010 -- With great effort and research into how to fight the HIV virus, important advancements in treatment have been made. What used to be a near-automatic death sentence is no longer the case. With the right mixture of medicines, an HIV-positive person can now live much longer than before. The HIV asymptomatic periods are now much longer than before as well, thanks to HIV research.
More Releases for HIV
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral